Exhibit 10.58

 

Work Order # 01

 

This Work Order #01 ("Work Order") dated May 16, 2014 ("Effective Date") is
entered into by and between Aethlon Medical Inc. ("Sponsor") and Total Renal
Research, Inc., d/b/a DaVita Clinical Research ("DCR"). Sponsor and DCR shall
each be hereinafter referred to as a "Party" and collectively as the "Parties".

 

Parties, this Work Order is entered into pursuant to the Master Services
Agreement by and between the Parties dated February 14, 2014, (the "Agreement"),
which is incorporated by reference herein.

 

Unless otherwise defined herein all capitalized terms shall have the same
meaning as in the Agreement.

 

The Parties hereby agree as follows:

 

1. Services. DCR shall conduct the Services as outlined in Attachment 1 attached
hereto, involving the Study Device entitled "A Clinical Safety Study of the
Aethlon HemopurifierrE0 in Chronic ESRD Patients with HCV Infection" (the
"Study"), bearing protocol ID# AEMD-IDE-2013 v1.09, dated March 31, 2014,
together with any of its subsequent revisions (the "Protocol"), the provisions
of which are attached hereto and incorporated herein by reference. The Protocol
may be revised only at the direction of and with the prior written approval of
the Sponsor, subject to subsequent approval by the Institutional Review Board
("IRB").

 

2. Deliverables. The Deliverables required to be delivered pursuant to this Work
Order shall include: Intentionally omitted.

 

3. Acceptance Criteria. The Acceptance Criteria for any such Deliverables shall
be as follows: Intentionally omitted.

 

4. Work Order Term. The term of this Work Order shall commence as of the
Effective Date and shall continue until the Services are completed, unless
otherwise agreed to by the parties ("Work Order Term"). If the Agreement expires
during the Work Order Term then the Parties specifically agree that this Work
Order shall survive and the terms of the Agreement shall continue to apply to
this Work Order during the Work Order Term.

 

5. Budget and Payment Schedule. Sponsor shall make payments to DCR for Fees and
Expenses in accordance with the terms of the Agreement and the Payment Schedule
attached hereto as Attachment 2.

 

6. Subcontractor. Through execution of this Work Order and the applicable
Clinical Trial Agreement or Investigator Agreement (form of which is attached
hereto as Attachment 4), Sponsor approves DCR's use of third party consulting
physicians (each an "Investigator") at certain sites, including a network of
dialysis centers owned and operated by a DCR affiliate (each a "Site").

 

 

1

 

 

7. Invoicing and Payment Detail.

 

A. Invoices to Sponsor shall be sent to Sponsor via e-mail at:

 

Name: Jim Frakes

e-mail: jfrakes@aethlonmedical.com

 

B. Payment to DCR shall be made electronically as follows:

 

Bank Name: Wells Fargo

Bank ABA/Routing #: XXXXXXX*

Account Name: Total Renal Research, Inc.

Account Number: XXXXXXX*

 

C. All payments shall reference project number: 13-M-0249-00

 

7. Conflict. To the extent that the terms of the attachments hereto conflict
with either the terms of the Agreement or this Work Order such terms shall be
controlled by the Agreement or Work Order, as applicable.

 

8. Delay of Study. In the event of a Sponsor derived postponement of
Hemopurifiere treatment (including but not limited to: Device shipment, Device
usability, Study approval by governing boards), or a Sponsor-derived
postponement or cancellation of the Study, Sponsor and DCR will negotiate the
cost consequences with the intent that DCR shall be paid for activities and
services earned (including any non-cancellable items) for their participation in
the Study.

 

The remainder of this page intentionally left blank.

 

Signatures to follow.

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

 

2

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Work Order to be executed by
their duly authorized representatives as of the Effective Date.

 

 

[ex1058_image1.jpg]

 

 

 

 

 

3

 

 

ATTACHMENT 1
Services

 

The following Services will be provided by DCR to Sponsor with respect to the
Study as described in the Sponsor Protocol and in accordance with the terms of
the Agreement:

 

1. Site Management and Clinical Study Conduct

 

A. DCR will conduct site management administrative services ("Services") for
Study Sites in accordance with the Protocol, attached hereto and incorporated
herein. The Services will include: (i) selection of Sites for the Study
including (1) the ability to enroll the desired number of patients; (2)
availability of an appropriate population to meet the inclusion and exclusion
criteria; (3) identification of proposed Investigators for each Site prior to
his/her participation in the Study (it being understood that Sponsor reserves
the right to approve or disapprove individual Investigators); and (4) confirming
that prospective, replacement and current clinical investigators are not listed
by the FDA as unacceptable to conduct clinical investigation; (ii) the
preparation of all Investigational Review Board (IRB) materials to be submitted
to a central IRB and assistance, as needed, to those Sites (if any) using their
own internal IRB; (iii) providing payments to Sites or Investigators, or both,
upon and subject to receipt of funds from Sponsor; (iv) providing or
coordinating ongoing onsite orientation and training of all Investigators and
their support personnel as needed with regard to compliance with the Protocol;
and (v) providing confirmation of accountability of Investigator performance
with regard to the following aspects of the Study conducted at the respective
Sites: (1) the number of subjects screened for the Study; (2) the number of
qualified subjects participating in the Study; and (3) the number of acceptable
completed case report forms resulting from the Study.

 

B. It is understood and agreed that Services shall not include the clinical
activities of any Investigator under an Investigator Agreement or a Clinical
Trial Agreement, as applicable, and that each Investigator is personally
responsible for the conduct of the Study in which s/he participates and shall
exercise his/her own independent medical judgment. DCR's responsibilities with
respect to Investigators shall be limited to those responsibilities specifically
set forth in this Work Order. DCR will contract with each Investigator for their
services on the Study using an Investigator Agreement or a Clinical Trial
Agreement, as applicable, substantially in the form attached hereto as
Attachment 4. DCR shall not perform the Study with an Investigator who has not
entered into an Investigator Agreement or for whom a Clinical Trial Agreement
has not been entered into.

 

C. DCR shall perform the Services and DCR shall inform the Investigator of
his/her obligation to perform the Study in compliance with generally accepted
standards of Good Clinical Practice as set forth in Title 21 of the U.S. Code of
Federal Regulations, the Protocol, instructions provided by Sponsor and all
applicable local, state and federal laws and regulations governing the
performance of clinical investigations including but not limited to the Federal
Food, Drug, and Cosmetic Act, and regulations and guidances of the U.S. Food and
Drug Administration (FDA), the Health Insurance Portability and Accountability
Act of 1996 ("HIPAA") and all other applicable medical privacy laws and
regulations; and any conditions imposed by the IRB.

 

4

 

 

D. The Study shall commence upon execution of this Work Order and the applicable
Investigator Agreement(s) or the Clinical Trial Agreement(s), as applicable. The
Study shall enroll up to ten (10) patients meeting all Protocol eligibility
requirements. Sponsor shall not be obligated to pay any sums for tests performed
on individuals who do not meet all Protocol eligibility criteria for the Study
or for additional individuals who are enrolled in the Study without Sponsor's
prior written approval. In the case where DCR enrolls ten (10) subjects, and one
or more subjects discontinues, DCR will contact Aethlon regarding enrollment of
additional subjects to meet Aethlon's primary endpoint. Notwithstanding the
foregoing, if Sponsor and DCR agree in writing to increase the number of
subjects for the Study, Sponsor shall pay DCR additional compensation for such
additional subjects as may be agreed upon between the parties.

 

E. DCR shall, as part of the Services, use its best efforts to cause all
Investigators to: (i) timely submit to DCR, Sponsor and/or Sponsor's designee,
clean and completed original case report forms for each Study subject as
provided in the Protocol; and (ii) provide to DCR (and DCR will then provide to
Sponsor) completed FDA form 1572 and sufficient accurate financial information
on FDA forms 3454/3455 to allow Sponsor to submit complete and accurate
certification or disclosure statements as required by 21 C.F.R. Part 54 and
promptly update this information if any relevant changes occur during the course
of each Study, and for one year following the completion of the Study.

 

F. At the completion of the Services for the Study by DCR or upon the earlier
termination of the Agreement or this Work Order, all materials, information and
all other data owned by Sponsor with respect to the transactions covered by this
Agreement, regardless of the method of storage or retrieval, shall be delivered
to Sponsor in such form as is then currently in the possession of DCR, or in
such data media formats as are set forth in the Protocol. Sponsor shall pay the
costs of delivery of such materials, information and other data from DCR to
Sponsor. Alternatively, at Sponsor's written request, such materials and data
may be retained by DCR for Sponsor for an agreed-upon time period, or disposed
of pursuant to the written directions of Sponsor. If materials are so retained,
Sponsor shall pay a to-be-determined fee for storage by DCR of records and
materials after completion or termination of the Services. DCR, however,
reserves the right to retain, at its own cost and subject to the confidentiality
provisions herein, copies of all materials that may be needed to satisfy
regulatory requirements or to resolve disputes regarding the Study.

 

G. During the term of this Agreement, DCR will permit Sponsor's representatives
(unless such representatives are competitors of DaVita HealthCare Partners Inc.)
to examine or audit the work performed hereunder upon reasonable advance notice
during regular business hours to determine that the Study is being conducted in
accordance with the Protocol. Any access to any Study Sites granted by DCR to
Sponsor's representatives hereunder shall be limited to purposes related to the
Study.

 

 

5

 

 

H. If Sponsor is providing Device for purposes of the Study, then neither
Investigators nor DCR shall bill third party payers for such Device. Neither
Investigators nor DCR shall bill third party payers for Study related items and
services except as permitted by applicable payer coverage rules.

 

 

 

 

 

 

 

 

 

 

6

 

 

ATTACHMENT 2

Payment Schedule, Payment Terms and Budget

 

1.0 Payment Terms

 

1.1 The Budget set forth herein is based on the specific charges applicable for
the Services. The Budget will change to reflect modifications in the scope of
Services. Applicable DCR service fees, as related to enrollment, will also
change with said modifications. Sponsor shall pay to DCR the amounts specified
in the Budget in accordance with the payment schedule outlined in the Payment
Schedule. The parties acknowledge and agree that the terms and conditions of the
Budget are confidential and shall be treated as Confidential Information in
accordance with the provisions of Section

 

11 of the Agreement. Payments will be reconciled as a part of the financial
reconciliation at the time of the final payment set forth in the Payment
Schedule.

 

1.2 Sponsor will reimburse DCR monthly on a completed-visit-per-Subject basis in
accordance with the Budget herein. In the event of an amendment to the Protocol
that modifies the Services to be provided under this Work Order, Sponsor and DCR
shall negotiate in good faith any modification to the payments hereunder in an
amount equal to the Services added or eliminated by the Protocol amendment and
agree to this change in writing (email is sufficient). Furthermore, pricing for
both Study Site and DCR Services may be subject to change in accordance with any
change in Study scope. Completed-visit-per-Subject payment due, including any
screen failure payments that may be payable under the terms of this Work Order,
will be made based upon prior month enrollment data as entered into the DCR
Clinical Trial Management System (CTMS) and on submission of an invoice by DCR
to this effect. All screen failures will be paid at the screening rate. DCR
shall, verify and reconcile this enrollment data with Sponsor, and appropriate
payment adjustments shall be made on the presentation of an invoice from DCR.
Sponsor shall provide proper documentation necessary to complete said
reconciliation. DCR Services will be invoiced to Sponsor in accordance with the
progression of the Study.

 

1.3 In the event of premature termination of this Work Order by Sponsor for any
reason other than for DCR's breach, Sponsor shall pay DCR for services performed
up to and including the date of termination and expenses incurred up until the
date of termination in accordance with the budgeted amounts set forth in the
Budget. Upon receipt of such notice of termination DCR will, and will direct the
study Site and Investigator to, take all reasonable steps to cease conduct of
the Study as soon as reasonably possible and to protect the safety, heath, and
welfare of the subjects participating the Study. The parties agree to work
collaboratively in the orderly termination of the study, under the direction of
the Sponsor. Sponsor shall pay DCR for the additional services involved in Study
termination, according to the amounts set forth in the Budget for such services
and other reasonable, documented Study procedures or expenses.

 

7

 

 

 

1.4 All payments shall be payable in U.S. dollars and made within thirty (30)
days of Sponsor’s receipt of an invoice dealing DCR’s Services under this Work
Order or incurrence of pass-through expenses, and only after full execution of
this Work Order. If any portion of any invoice is disputed, then Sponsor shall
pay the undisputed amounts as set forth in the preceding sentence and the
Parties shall use good faith efforts to reconcile the disputed amount as soon as
practicable. Sponsor shall pay DCR interest in an amount equal to one percent
(1%) per month (or the maximum lesser amount permitted by law) of all undisputed
amounts owing hereunder and not paid within forty-five (45) days of the date of
the invoice.

 

1.5 DCR shall be responsible for making monthly payments to the Site and
Investigator upon Site’s entry of completed study activities into the Clinical
Trrial Management System (CTMS).

 

1.6 Terms of the budget shall remain confidential.

 

2.0 Payment Schedule

 

[ex1058_image2.jpg] 

Patient compensation for study time and effort will be paid to DCR on a monthly
bases with the concurrent study visit payment. Patients will be compensated for
each completed visit by the Study Site. Payment for patients who are terminated
prior to the end of the study will be prorated for actual visits completed.

 

 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

8

 

 

2.2 DCR Project Management of XXXXXXX* of the total invoiced patient and site
pricing costs will be added to each monthly invoice.

 

2.3 All per occurrence fees and pass through costs payable hereunder shall be
paid in full within 30 days of Sponsor's receipt of invoice from DCR.

 

2.4 Disposal fee for used Hemopurifier will be paid by Sponsor to DCR following
last patient last visit.

 

2.5 The following will be retained for each Site in the Study:-

 

i) Site Close Out Visit

 

iii) Record Storage Fee

 

Which will be paid by Sponsor to DCR promptly following the occurrence of all of
the following events: a) final acceptance by Sponsor of all CRFs b) all data
clarifications issued, and c) upon satisfaction of all other applicable
conditions set forth in the Agreement. Sponsor shall make all efforts to
complete these activities in a timely basis. Sponsor shall notify DCR upon each
site's official completion of the above conditions.

 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

9

 

 

 [ex1058_image3.jpg]

 

 

 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

10

 

 

 [ex1058_image4.jpg]

 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

 

11

 

 

ATTACHMENT 4

 

Form of Clinical Trial Agreement

 

CLINICAL TRIAL AGREEMENT

 

This Clinical Trial Agreement (Agreement), effective as of __________________ ,
2014, is entered into by and among [NAME OF INSTITUTION] (Institution), Total
Renal Research, Inc., d/b/a DaVita Clinical Research with offices located at 825
South 8th Street, Suite 300, Minneapolis, MN 55404 (DCR), Aethlon Medical Inc.
with offices located at 8910 University Center Lane, Suite 660, San Diego, CA
92122 (Sponsor) and [NAME OF INVESTIGATOR], M.D. (Investigator).

 

Background

Sponsor is engaged in research and development of blood purification medical
devices including the conduct of clinical trials involving the use of
Hemopurifier® (Study Device). Institution and the Investigator are engaged in
the treatment of patients with chronic early stage renal disease. Sponsor and
DCR have entered into a Master Services Agreement and Work Order pursuant to
which DCR will provide site management services in connection with the Study (as
defined below). The clinical study contemplated by this Agreement (the Study) is
of mutual interest and benefit to the Institution, Investigator and Sponsor; and
Sponsor Protocol No. ID# AEMD-IDE-2014 entitled ""A Clinical Safety Study of the
Aethlon Hemopurifie? in Chronic ESRD Patients with HCV Infection"," dated May
13, 2013, which shall guide the performance of the Study has been prepared by
Sponsor and accepted by the Institution and DCR (such protocol, together with
any of its subsequent amendments, the Protocol).

 

NOW, THEREFORE, in consideration of the foregoing premises and the covenants
contained herein the parties agree as follows:

 

1. SCOPE OF WORK

The Investigator shall carry out the Study in a professional, competent manner
in accordance with the Protocol, the terms of this Agreement and any applicable
Institution policies. Institution shall use its best efforts to ensure that the
Investigator shall carry out the Study in accordance with the Protocol and the
terms of this Agreement. The Protocol shall be provided to DCR and the
Investigator by Sponsor.

 

2. PERFORMANCE PERIOD AND ENROLLMENT OF SUBJECTS

The Study will commence upon execution of this Agreement and will continue until
completion of the Study as required by the Protocol (including any amendments
thereto), unless this Agreement is terminated earlier pursuant to Section 5
hereof.

 

3. SERIOUS ADVERSE EXPERIENCE REPORTING

If Institution and/or Investigator receives notice of a Serious Adverse
Experience (defined herein) related to the investigational Device, Institution
and/or Investigator shall provide Sponsor with notice within twenty-four (24)
hours of learning of the event and provide such additional information
thereafter as reasonably requested by Sponsor. Furthermore, upon Sponsor's
reasonable request, Institution and/or Investigator shall promptly investigate
any such Serious Adverse Experience and shall submit follow-up reports of new
information in a timely manner. "Serious Adverse Experience" refers to an
experience that has any serious adverse effect on health or safety or any
life-threatening problem caused by, or associated with, a Device, if that
effect, problem, or death was not previously identified in nature, severity, or
degree of incidence in the investigational plan or application, or any other
unanticipated serious problem associated with a Device that relates to the
rights, safety, or welfare of subjects. Any untoward event which occurs
regardless of its causality, including any side effect, injury, toxicity or
sensitivity reaction during the testing of protocol treatments (whether or not
considered Device-related), will be designated as an unanticipated adverse
effect and recorded on the adverse events page of the Case Report Form (CRF).

 

12

 

 

4. PAYMENT

Cost and payment terms are set forth in Exhibit A of this Agreement and
incorporated herein by reference. The parties acknowledge and agree that, as
between DCR, Institution and Investigator, the terms and conditions of Exhibit A
are confidential and shall be treated by DCR, Institution and Investigator as
Confidential Information in accordance with the terms and conditions of Section
6.2 of this Agreement. Without limiting the generality of the foregoing, neither
DCR, nor Sponsor, nor Institution, nor Investigator shall disclose the terms and
conditions of Exhibit A without the prior written consent of the others, unless
such disclosure is required by applicable law. Institution represents and
warrants that the compensation provided under the terms of this Agreement shall
be consistent with fair market value in arm's length transactions, and has not
been determined in any manner with regard to, or has been given in exchange for,
any implicit or explicit agreement to provide favorable procurement decisions
with regard to Sponsor's products, or to the value or volume of any business
generated between the parties, and that the services to be performed under the
Agreement do not and will not involve the counseling or promotion of a business
arrangement or other activity that violates any state or federal law.

 

5. TERMINATION

A. This Agreement may be terminated:

(1)by DCR or the Institution upon thirty (30) days' prior written notice;

(2)by Sponsor immediately upon written notice;

(3)by either DCR, the Institution or Sponsor immediately if the Investigator is
unable to continue to serve and a successor acceptable to both the Institution
and Sponsor is not available; or

(4)by either DCR, the Institution or Sponsor upon the occurrence of an event
qualifying as a termination event as described in the Protocol.

 

B. Immediately upon receipt of a notice of termination, the Investigator shall
stop enrolling Subjects into the Study and shall cease conducting procedures on
Subjects already enrolled in the Protocol as directed by Sponsor, to the extent
medically permissible and appropriate.

 

C. In the event that this Agreement is terminated in accordance with Section
5.A, DCR will credit or return to Sponsor any funds not expended or obligated by
the Institution in connection with the Study prior to the effective termination
date.

 

D. Upon the effective date of termination, DCR shall conduct an accounting of
expenses chargeable to Sponsor. Sponsor shall verify the charges presented by
DCR and if Sponsor objects to any charge, the parties shall use best efforts to
resolve expeditiously any disagreement. Within thirty (30) days after receipt of
adequate documentation or resolution of any dispute, Sponsor shall make payment
to DCR for:

13

 

 

(1)all services properly rendered and monies properly expended by the
Institution prior to the date of termination and not yet paid for; and

(2)reasonable non-cancelable obligations properly incurred for the Study by the
Institution prior to the effective date of termination.

 

E. Termination of this Agreement by any party shall not affect the rights and
obligations of the parties accrued prior to the effective date of the
termination. The rights and duties under Sections 4, 5, 6, 7, 8, 9, 11, 12, and
13.1-13.9 survive the termination or expiration of this Agreement.

 

6. CONFIDENTIALITY
6.1 Publicity.

A. Except as is necessary to comply with applicable laws and regulations or to
enforce their respective rights under this Agreement, or to a party's legal or
financial advisors, and except as otherwise agreed to by the parties in writing,
the parties shall keep the material terms of this Agreement confidential. If
this Agreement is required to be filed by any party with the Securities and
Exchange Commission, such party shall not file this Agreement with the
Securities and Exchange Commission without first notifying the other parties and
seeking confidential treatment for any provisions of this Agreement that any
other party believes would disclose trade secrets, confidential commercial or
financial information that would impair the value of the contractual rights
represented by this Agreement or provide detailed commercial and financial
information to competitors or third parties.

 

B. No party shall make (or have made on its behalf) any oral or written release
of any statement, information, advertisement or publicity in connection with
this Agreement which uses the other party's name, symbols, or trademarks without
the other party's prior written approval. The obligations of this Section shall
survive termination of this Agreement.

 

C. Study results may not be published or referred to, in whole or in part, by
Investigators without the prior expressed written consent of Sponsor. Sponsor
shall include, or cause to be included in any reports, presentations, and
publications it makes concerning the Study a statement that clearly indicates
the role of DaVita Healthcare Partners Inc. as a clinical research site for such
Study.

 

6.2 Confidentiality.

A. "Confidential Information" means any and all information, data, and know-how,
whether written or oral, technical or non-technical, including, without
limitation, any financial, business, marketing, or operations information,
formulas, manufacturing processes, basic scientific data, prior clinical data,
Data (defined herein) or other information provided by or on behalf of a Party
or its Affiliates (the Disclosing Party) to the other Party pursuant to this
Agreement (the Receiving Party). As between DCR, Institution and Investigator,
Confidential Information shall also include the terms and conditions of Exhibit
A of this Agreement.

 

14

 

 

 

B. Confidential Information shall remain the sole and exclusive property of the
Disclosing Party. For a period of five (5) years after the receipt of
Confidential Information hereunder, the Receiving Party agrees to hold such
Confidential Information in confidence, to only use such Confidential
Information for the purposes of this Agreement and to only disclose such
Confidential Information to its employees, agents, Affiliates, contractors and
representatives who are bound by an obligation of confidentiality. Receiving
Party also agrees to use the same degree of care to avoid disclosure of such
Confidential Information as the parties employ with respect to their own
confidential information of like importance, but in no event less than a
reasonable amount of care;

 

C. Exceptions. Confidential Information shall not include information that:

 

(i) at the time of disclosure, or thereafter, has become publicly available,
except by breach of this Agreement;

(ii) was in the possession of the Receiving Party prior to disclosure hereunder
as evidenced by competent records;

(iii) was developed by a Receiving Party independently from and without
reference to Confidential Information received hereunder; or

(iv) a Receiving Party received from a third party without an obligation of
confidentiality.

 

D. Compliance with Applicable Law. Notwithstanding any other terms contained
herein, a Receiving Party may disclose Confidential Information received
hereunder to the extent required by applicable law provided that such Receiving
Party provides notice to the Disclosing Party as soon as reasonably practicable
under the circumstances and agrees to cooperate in Disclosing Party's efforts to
obtain a protective order or other appropriate remedy. Any information disclosed
pursuant to this paragraph shall otherwise remain Confidential Information.

 

E. Return of Confidential Information. Upon request of a Disclosing Party, a
Receiving Party shall return to such Disclosing Party all Confidential
Information received from that Disclosing Party pursuant to this Agreement.

 

F. Subject Information. If DCR, Institution, Investigator, Sponsor or Sponsor's
Designee (as defined below) shall come into contact with any Study Subject's
medical records, each of them shall hold in confidence the identity of such
Subject and shall comply with all applicable law(s) regarding the
confidentiality of such subject's records. To the extent that DCR, the
Investigators, or any other person or entity involved in the Study (other than
as a subject) is a "covered entity" under the Health Insurance Portability and
Accountability Act of 1996 (HIPAA), DCR warrants that DCR will cause
Investigators to obtain a valid HIPAA Privacy Rule authorization, as prescribed
in 45 C.F.R. §164.508(b) from each individual participating in the Study
permitting disclosures from DCR and/or the Investigators to Sponsor and any and
all other clinical trial service providers of the individual's "protected health
information" (as defined in HIPAA) as required by and in accordance with the
Study, which such authorization will permit Sponsor's use [and disclosure] of
such protected health information for the purposes of monitoring the accuracy
and completeness of the research data, performing clinical and scientific
research, and medical product development.

 

15

 

 

7. PROPRIETARY RIGHTS

A. All information directly resulting from the Study conducted under this
Agreement, including all Data (as defined herein), results, conclusions,
discoveries, inventions, know-how and the like, whether patentable or not
(collectively, Inventions) shall be promptly and fully disclosed by Institution
and/or Investigator to Sponsor. Data shall mean all case report forms and other
Study data generated by DCR, Institution or Investigator in the course of
conducting the Study and required to be delivered to Sponsor pursuant to the
Protocol.

 

B. Sponsor shall have the unrestricted right to freely utilize all such
Inventions in whatever manner it desires. All Inventions shall be the sole
property of Sponsor excluding the identity of any Study Subject or such
Subject's "protected health information" (as defined in the HIPAA Privacy Rule)
unless the Subject has provided authorization or a waiver has been provided.
Institution and/or Investigator shall assist Sponsor, at Sponsor's expense, in
the preparation of all documentation necessary to effectuate and perfect
Sponsor's rights in such Inventions.

 

C. The use of the Study Device by DCR, the Institution or the Investigator for
any purpose outside of the Study is prohibited by this Agreement. While Sponsor
in no way condones the use of the Study Device for any purpose outside of the
Study, if such work is performed, all data, results, conclusions, observations,
discoveries, inventions, ideas, know-how, procedures, advancements and the like,
whether patentable or not, shall be treated in all respects as Inventions in
accordance with this Agreement and shall be the sole property of Sponsor.

 

D. Neither Sponsor, DCR, nor the Institution transfers to the other by operation
of this Agreement any patent right, copyright right, or other proprietary right
of any party, except as described in this Agreement.

 

8. PUBLICATION

Neither DCR, Institution nor Investigator shall publish any articles or make any
presentations relating to the services, Sponsor Confidential Information or
referring to Data generated pursuant to this Agreement, without the prior
written consent of Sponsor.

 

9. CHANGES TO THE PROTOCOL

A. If generally accepted standards of Good Clinical Practice as set forth in
Title 21 of the U.S. Code of Federal Regulations (C.F.R.) (GCP) relating to the
safety of Subjects require a deviation from the Protocol, these standards shall
be followed. Any party who becomes aware of the need for a deviation from the
Protocol shall immediately inform the other parties to this Agreement of the
facts causing the deviation as soon as the facts are known to the party. In
addition, the Investigator shall promptly inform the Institution's institutional
review board ("IRB") of the deviation.

 

16

 

 

B. Sponsor may also, from time to time, make changes to the Protocol. Any such
changes may not be implemented before approval by the IRB. If these changes
shall affect the cost of the Study, DCR and Sponsor shall agree to the changes
in Exhibit A to reflect the changes in the Study cost and the change shall not
be implemented until Sponsor agrees in writing to assume responsibility for the
new costs.

 

10. MATERIALS

Sponsor agrees to provide Study Device and any reagents that may be required
during the course of the Study. Access to any Materials shall be limited to only
those persons who, under the Investigator's direct control, shall be using
Materials for the Study. The term "Materials" shall include the Study Device,
reagents and materials derived from Subjects enrolled in the Study, including,
but not limited to, blood, bone marrow, sera, and other biological materials. At
no time shall any Materials be used for any purpose other than as described in
the Protocol or transferred to any third party without Sponsor's prior written
consent. Upon termination or completion of the Study, all unused Materials shall
be returned to Sponsor or destroyed at Sponsor's sole option; provided, however,
that Institution shall be permitted to retain blood, bone marrow, sera, and
other biological materials as needed for record keeping purposes in accordance
with Institution's policies and practices.

 

11. COMPLIANCE WITH LAW AND ACCEPTED PRACTICE

A. The Institution and the Investigator shall perform the Study in compliance
with generally accepted standards of GCP, the Protocol, consistent instructions
provided by Sponsor and all applicable local, state and federal laws governing
the performance of clinical investigations including but not limited to the
Federal Food, Drug, and Cosmetic Act, regulations and guidances of the United
States Food and Drug Administration (FDA). The Institution and Investigator
shall permit Sponsor and agencies such as the FDA to inspect Study records
including the Subjects' medical records. The subject informed consent form
signed by the Subjects shall provide for access to the Subjects' medical records
by Sponsor and by agencies such as the FDA.

 

B. The Investigator will direct and monitorthe Study in accordance with Section
1. Sponsor shall have the right to (a) monitor and audit the activities of the
Investigator in the conduct of the Study, and (b) monitor and audit the
collection of Inventions from the Study.

 

C. Each of the Institution and Investigator hereby represents and warrants that
neither the Institution, the Investigator, nor any of the Institution's nor
Investigator's agents or employees rendering services in connection with the
Study, respectively,is presently: (1) excluded, debarred, suspended or otherwise
ineligible to participate in federal health care programs as defined in 42
U.S.C. Sec. 1320a-7b or from federal procurement or non-procurement activities
as defined in Executive Order 12689 (collectively "Ineligible"); or (2) debarred
pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335 (a), as
amended, or any similar state law or regulation (collectively "Debarred") or;
(3) convicted of a criminal offense that falls within the ambit of 42 U.S.C. Sec
1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise
declared ineligible ("Convicted"). The Institution and Investigator also each
represent and warrant that if any of their respective agents or employees
becomes Ineligible, Debarred or Convicted during the Term, they will notify
Sponsor promptly, and in any event no later than five (5) business days after
receiving notification of the Ineligibility, Debarment, or Conviction.

 

17

 

 

D. The arrangements set out in this Agreement do not take effect and are not
intended to take effect as an incentive or reward for a person's past, present
or future willingness to prescribe, administer, recommend (including formulary
recommendations), purchase, pay for, reimburse, authorize, approve or supply any
product or service sold or provided by Sponsor or as an incentive to grant an
interview for any sales or marketing purposes.

 

E. The parties shall not pay or promise to pay, or authorize the payment of any
money, or give, promise to give or authorize the giving of anything of value to
any government official, healthcare professional or person affiliated with a
healthcare organization to obtain or retain business or secure improper
advantage. Further, the parties represent and warrant that they have not made
prior to the Effective Date any payment, authorization, promise or gift of the
sort described in this paragraph.

 

F. The parties shall comply with the requirements of the U.S. Foreign Corrupt
Practices Act and any other applicable anti-corruption national or international
laws and regulations. Further, each party hereby represents, warrants and
covenants that they have not, and agrees that it will not, in connection with
the transactions contemplated by this Agreement, make, promise or offer to make
any payment or transfer anything of value: (a) to any foreign government
official or to an intermediary for payment to any foreign government officials;
or (b) to any political party. Further, no payments or transfer of value shall
be made which have the purpose or effect of public or commercial bribery,
acceptance of or acquiescence in extortion, kickbacks or other unlawful or
improper means of obtaining or retaining business.

 

G. If any governmental or regulatory authority conducts or gives notice to
Institution of its intent to conduct an inspection at Institution's facilities
or take any other regulatory action with respect to the Study, Institution will
promptly give Sponsor notice thereof, including all information pertinent
thereto. Sponsor acknowledges that Sponsor may not direct the manner in which
Institution fulfills its obligations to permit inspection by governmental
entities. It shall not be a breach of this Agreement for Institution to comply
with the demands and requests of any governmental entity in accordance with
Institution's judgment or to fail to inform and consult with Sponsor before
complying with any such demand or request. Except as permitted by this section,
neither Institution nor Investigator shall communicate with the FDA or any other
governmental agency concerning the subject matter hereof unless required by law
or requested to do so by Sponsor and, then, only upon prior consultation with
Sponsor.

 

H. Neither DCR, Investigator nor Institution shall bill third party payers for
Study related items and services except as permitted by applicable payer
coverage rules.

 

12. INDEMNIFICATION, DISCLAIMER AND INSURANCE

 

18

 

 

A. Subject to the provisions of Section 12.D, Sponsor will defend, indemnify and
hold harmless DCR, Investigator, Institution, and DCR's and Institution's parent
corporations, affiliates, officers, directors, employees, agents, and their
successors and assigns (each, a Indemnified Party) from and against any and all
costs (including reasonable attorneys' fees), expenses, damages and judgments or
liabilities (collectively, Losses) arising from or related to any third party
claims, demands, actions or suits, for illness or personal or bodily injury
(including death) to a Subject participating in the Study. The foregoing
indemnification action shall not apply in the event and to the extent that (a)
such Losses are determined to have resulted from any Indemnified Party's gross
negligence, intentional misconduct or negligence; or (b) Investigator(s) or
those assisting them did not adhere to the terms of the Protocol and to
Sponsor's written instructions relative to the use of substances administered in
the Study or failed to employ reasonable care in the conduct of the Study in
conformity with the generally accepted standards of the medical community or
violated any applicable laws or regulations in any material respect. For
purposes of this Section 12.A, a violation shall be deemed "material" if it
adversely affects the safety, health or welfare of Study subjects.

 

B. It is understood and agreed that, Investigators are not employees or agents
of DCR and that DCR shall not be required to indemnify Sponsor or its agents or
employees for any claims, suits or damages arising as a result of, or in
connection with, the willful misconduct or negligent acts or omissions of any
Investigator. DCR shall, however, cause each Investigator to maintain
professional liability insurance with policy limits of at least $1,000,000 per
claim and $3,000,000 annual aggregate.

 

C. In the event a Subject participating in the Study suffers an illness or
injury which the Investigator and Sponsor reasonably determine to be an adverse
reaction to the Sponsor material being tested in the Study or Study procedures
required by the Protocol then, subject to the Indemnified Party's compliance
with Section 12.D, Sponsor shall pay all necessary and reasonable medical
expenses directly associated with the emergency medical treatment of such
adverse reaction. In the event diagnostic procedures are required to determine
the etiology of the patient's symptoms, Sponsor shall pay the reasonable expense
of such diagnostic work-up without regard to the final diagnosis, so long as
Sponsor agrees to the need for the diagnostic work-up, but Sponsor shall not be
responsible for expenses connected with the subsequent treatment of the patient
if the work-up establishes that the patient's symptomology is not related to the
administration of the Sponsor material being tested in the Study or Study
procedures required by the Protocol. Payments under this Section 12.0 shall be
in addition to any payments specified in Section 12.A.

 

D. To receive the benefit of indemnification under Section 12.A, the Indemnified
Party must promptly notify Sponsor in writing of a claim or suit and provide
reasonable cooperation (at Sponsor's expense) and tender to the Sponsor
authority to defend or settle the claim or suit; provided, however, that Sponsor
shall not enter into any settlement of any claim that is based on any admission
of liability by an Indemnified Party without such Indemnified Party's consent.
Sponsor has no obligation to indemnify the Indemnified Party in connection with
any settlement made without the Sponsor's written consent. The Indemnified Party
has the right to participate at its own expense in the claim or suit and in
selecting its own counsel therefor. The Indemnified Party shall cooperate with
Sponsor, as reasonably requested, at Sponsor's cost and expense.

 

19

 

 

E. EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 6.2 AND EXCEPT
AS OTHERWISE PROVIDED IN SECTION 12.A WITH RESPECT TO THIRD PARTY CLAIMS IN NO
EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER FOR PUNITIVE, EXEMPLARY,
CONSEQUENTIAL, INCIDENTAL, SPECIAL, OR INDIRECT DAMAGES, INCLUDING LOSS OF
PROFITS, IN TORT OR CONTRACT, AS A RESULT OF THIS AGREEMENT.

 

13. GENERAL PROVISIONS.

13.1 Governing Law. This Agreement shall be governed and construed in accordance
with the laws of Delaware to the exclusion of any choice or conflict of laws
rule or provision that would result in the application of the substantive law of
any other jurisdiction.

 

13.2 Amendment and Waiver. No provision of or right under this Agreement shall
be deemed to have been waived by any act or acquiescence on the part of any
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by any party of any breach of
this Agreement by any other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

 

13.3 Relationship of the Parties. In the activities connected with the Study,
DCR, Institution and Investigator are, and shall in all respects act as,
independent contractors without the capacity to bind Sponsor or any other party,
and DCR, Institution and Investigator also agree that they are not acting as
agents or employees of Sponsor. Notwithstanding anything contained in this
Agreement to the contrary, DCR, Institution and Investigator shall not initiate
or participate in any communications with the FDA or any other governmental
agency concerning the subject matter hereof unless required by law or requested
to do so by Sponsor and, then, only upon prior consultation with Sponsor.

 

13.4 Assignment. Neither the Institution nor the Investigator may assign or
transfer any of their rights or obligations under this Agreement without the
prior written consent of Sponsor and DCR. Any attempted assignment in violation
of the provisions of this Section 13.4 will be void. This Agreement shall bind
and inure to the benefit of the parties hereto and their respective successors
and permitted assigns.

 

13.5 Notices. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be sent by registered or
certified mail, postage prepaid, or by overnight courier service. Notices may be
sent by facsimile or e-mail, if confirmed by also sending as described above.

 

13.6 Severability. If any provision(s) of this Agreement should be illegal or
unenforceable in any respect, the legality and enforceability of the remaining
provisions of this Agreement shall not in any way be affected.

 

20

 

 

13.7 Captions; Word Meanings. Captions of the sections and subsections of this
Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or
construction of the terms and conditions hereof. Words such as herein,
hereinafter, hereof and hereunder refer to this Agreement as a whole and not
merely to a section or paragraph in which such words appear, unless the context
otherwise requires. The singular shall include the plural, and each masculine,
feminine and neuter reference shall include and refer also to the others, unless
the context otherwise requires.

 

13.8 Entire Agreement. This Agreement (including Exhibit A and the Protocol)
represents the entire and integrated agreement between the Parties and
supersedes all prior negotiations, representations or agreements, either written
or oral, regarding its subject matter

 

13.9 Conflict or Inconsistency. In case of a conflict between this Agreement and
the Protocol, this Agreement shall control. The parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be construed against any party by reason
of the extent to which such party or its professional advisors participated in
the preparation of this Agreement.

 

13.10 Counterparts. This Agreement and any Work Order may be executed in one or
more counterparts, including .PDF copies or counterparts submitted by facsimile,
each of which shall be deemed an original and all of which shall constitute the
same instrument.

 

13.11 Further Assurances. Each party covenants and agrees that, subsequent to
the execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

 

(signature page follows]

 

21

 

 

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

 

[ex1058_image5.jpg] 

 

22

 

CONFIDENTIAL

DO NOT REPRODUCE OR DISCLOSE

 

Exhibit A

BUDGET, PAYMENT TERMS AND PAYMENT SCHEDULE

[BUDGET TO BE ATTACHED]

 

1.0 Payment Terms.

 

1.1 The Budget set forth herein is based on the specific charges applicable for
the services of the Institution and/or Investigator. Sponsor shall pay to DCR
the amounts specified in The Budget in accordance with the payment schedule
outlined in the Payment Schedule outlined below in section 2.0. DCR shall then
pay the Institution and/or Investigator monthly payments upon entry of completed
study activities into the Clinical Trial Management System (CTMS). The parties
acknowledge and agree that the terms and conditions of The Budget are
confidential and shall be treated as Confidential Information in accordance with
the provisions of Section 4 of this Agreement. Payments will be reconciled as a
part of the financial reconciliation at the time of the final payment set forth
in the Payment Schedule.

 

1.2 In the event of an amendment to the Protocol that modifies the services to
be provided under this Agreement, Sponsor and DCR shall negotiate any
modification to the payments hereunder in an amount equal to the services added
or eliminated by the Protocol amendment and agree to this change in writing
(email is sufficient). Furthermore, pricing for Institution and/or Investigator
services may be subject to change in accordance with any change in Study scope.
Completed-visit-per-Subject payment due, including any screen failure payments
that may be payable under the terms of this Agreement, will be made based upon
prior month enrollment data as entered into the DCR Clinical Trial Management
System (CTMS). All screen failures will be paid at the screening rate. DCR
shall, at its discretion, verify and reconcile this enrollment data with
Sponsor, and appropriate payment adjustments from Sponsor shall be made on the
presentation of an invoice from DCR, or as to Study Site, at DCR's discretion.
Sponsor or designee shall provide proper documentation necessary to complete
said reconciliation.

 

1.3 All amounts required to be paid by DCR to Institution and/or Investigator
under this Agreement are exclusive of any and all duties and taxes, however
designated, levied or based on this Agreement or the Services delivered
hereunder, including, without limitation, any personal property, retail sales,
goods and services, use or value added taxes and whether such taxes are now in
force or subsequently levied. Sponsor shall pay and be responsible for all such
taxes (excluding taxes based on DCR's net income and the Federal Insurance
Contributions Act, workers' compensation, unemployment and withholding taxes
concerning DCR personnel). Sponsor shall promptly reimburse DCR for any such
taxes which DCR pays directly.

 

23

 

 

 [ex1058_image6.jpg]

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

24

 

 

FIRST AMENDMENT TO WORK ORDER #01

 

This First Amendment (the "Amendment") to Work Order #01 (the "Work Order") is
made and entered into effective as of the 71h day of January, 2015, (the
"Effective Date") by and between Aethlon Medical Inc. with offices located at
8910 University Center Lane, Suite 660, San Diego, CA 92122 (hereinafter
referred to as "Sponsor"), and Total Renal Research, Inc. d/b/a DaVita Clinical
Research with offices located at 825 South 8th Street, Suite 300, Minneapolis,
MN 55404 ("DCR"). Sponsor and DCR shall each be hereinafter referred to as a
"Party" and collectively as the "Parties".

 

WHEREAS, the Parties entered into the Work Order on the 16th day of May, 2014,
pursuant to the Master Services Agreement effective the 14th day of February,
2014 (the "Agreement");

 

WHEREAS, the Parties wish to amend the terms of the Work Order as outlined in
this Amendment;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants in the
Agreement, Work Order and this Amendment, the Parties agree as follows:

 

1.Attachment 3, Study Conduct and Site Management Services Budget is hereby
deleted in its entirety and replaced with the attached Study Conduct and Site
Management Services Budget to reflect the addition of:    ·     Study Subject
travel expense reimbursement    ·     Central lab identification assistance and
protocol amendment review    ·     IStat Celite Act Cartridges procurement     
2.Sponsor hereby agrees that DCR shall procure, and Sponsor shall pay for, the
iStat Celite Act Cartridges ("Cartridges") for use in the Study. Cartridges will
be procured in quantities of twenty-five (25) Cartridges per box. DCR shall
invoice Sponsor, and Sponsor shall reimburse DCR, the current market price of
each box of Cartridges. Any unused Cartridges shall, at Sponsor's expense, be
shipped to Sponsor or destroyed, as requested by Sponsor in writing (for which
email shall suffice). In addition, DCR shall invoice and Sponsor shall pay to
DCR an administrative fee of XXXXXXXX* of the total cost of each Cartridge box
procured for the Study. Sponsor shall pay DCR in accordance with the terms of
the Agreement and Work Order.

 

3.Except as stated in this Amendment all terms and conditions of the Agreement
and Work Order remain in full force and effect.

 

 

Signature page follows

 

 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

25

 

 

 [ex1058_image7.jpg]

 

26

 

 

[ex1058_image8.jpg] 

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

 

27

 

 

 [ex1058_image9.jpg]

 

[*] This material has been omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission.

28